Sign up for the QMED & MD+DI Daily newsletter.
March 17, 2017
6 Slides
Two-year data from Medtronic’s Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) trial was presented at the American College of Cardiology meeting in Washington. The data was also published in The New England Journal of Medicine.The SURTAVI trial is a global, prospective, multi-center, randomized study evaluating Medtronic’s Corevalve and Corevalve Evolut R systems versus to open-heart surgery at two years. The trial enrolled intermediate risk (IR) patients and compared 863 transcatheter aortic valve replacement (TAVR) patients to 794 surgical aortic valve replacement (SAVR) patients.Don't miss BIOMEDevice Boston, May 3-4, 2017. [Image credit: MEDTRONIC]
Two-year data from Medtronic’s Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) trial was presented at the American College of Cardiology meeting in Washington. The data was also published in The New England Journal of Medicine.
The SURTAVI trial is a global, prospective, multi-center, randomized study evaluating Medtronic’s Corevalve and Corevalve Evolut R systems versus to open-heart surgery at two years. The trial enrolled intermediate risk (IR) patients and compared 863 transcatheter aortic valve replacement (TAVR) patients to 794 surgical aortic valve replacement (SAVR) patients.
[Image credit: MEDTRONIC]
You May Also Like
